drugs in development for SMA spinal muscular atrophy

Repligen Corp. is proceeding with development of an experimental compound to treat spinal muscular atrophy, with help from a new MDA grant

posted on December 15, 2010 - 9:08am
MDA has awarded a $1.4 million grant to the biopharmaceutical company Repligen Corp. to help advance the company’s experimental drug for spinal muscular atrophy (SMA) to phase 1 human clinical trials. The drug, RG3039, has demonstrated potential throughout its early development, and is Repligen's lead therapeutic candidate for treatment of SMA.

New content is being added every day. Please check back again.